

IN THE CLAIMS

~~Please cancel claims 1-6, and 11-19.~~

Please amend claims 7, 8, and 20 as follows:

1 7. (Amended) A binding compound comprising an antigen binding site from an
2 antibody, which specifically binds to a mature polypeptide comprising at least 8 contiguous
3 amino acid residues from[:]

- a)] SEQ ID NO: 2[;
- b) SEQ ID NO: 6;
- c) SEQ ID NO: 13; or
- d) SEQ ID NO: 15].

1 ||

8. (Amended) The binding compound of Claim 7, wherein:

- a)] said binding compound is an Fv, Fab, or Fab2 fragment[;
- b) said binding compound is conjugated to another chemical moiety; or
- c) said antibody:
 - i) is raised against a polypeptide comprising a 12 consecutive amino acid segment of SEQ ID NO: 2, 6, 13, or 15;
 - ii) is raised against a mature IL-1 ϵ ;
 - iii) is raised to a purified rodent IL-1 δ or rodent or primate IL-1 ϵ ;
 - iv) is immunoselected;
 - v) is a polyclonal antibody;
 - vi) binds to a denatured IL-1 δ or IL-1 ϵ ;
 - vii) exhibits a Kd to antigen of at least 30 μ M;
 - viii) is attached to a solid substrate, including a bead or plastic membrane
 - ix) is in a sterile composition; or
 - x) is detectably labeled, including a radioactive or fluorescent label.

1

20. (Amended) A method of:
A) making an antiserum comprising an antibody of Claim 7, comprising immunizing a mammal with an immunogenic amount of 5

- a) a rodent IL-1 δ polypeptide;
- b)] a peptide [sequence] comprising a 12 consecutive amino acid segment of SEQ ID NO: 2;
- [c) a rodent or primate IL-1 ϵ polypeptide; or

A3
Cm.⁺

9 d) a peptide sequence comprising a 12 consecutive amino acid segment of
10 SEQ ID NO: 6, 13, or 15;]
11 thereby causing said antiserum to be produced; or
12
13 A3
14 Cmld
15 B) producing an antigen:antibody complex, comprising contacting [:
16 a)] a rodent IL-1 δ protein or peptide with [an antibody] a binding
17 compound of Claim 7; [or
18 b) a rodent or primate IL-1 ϵ protein or peptide with an antibody of Claim
19 7;]
20 thereby allowing said complex to form.

21 A4
22 Cmld
23 Please add new claims 21-25 as follows:

24 21. (New) The binding compound of Claim 7, wherein said antibody is a
25 polyclonal antibody.

26 22. (New) The binding compound of Claim 7, wherein said antibody is
27 detectably labeled.

28 23. (New) The binding compound of claim 7, wherein said at least 8
29 contiguous amino acid residues of SEQ ID NO:2 is selected from the group consisting of
30 residues 8-24; 27-48; 56-73; 77-106; 108-125; 130-156; and 74-98.

31 24. (New) The binding compound of claim 7, wherein said polypeptide
32 comprises at least 12 contiguous amino acid residues from SEQ ID NO: 2.

33 25. (New) The binding compound of claim 24, wherein said 12 consecutive
34 amino acid segment is selected from:
35 (1) LeuCysPheArgMetLysAspSerAlaLeuLysValLeuTyrLeuHisAsn-Asn;
36 (2) IleSerValValProAsnArgAlaLeuAspAlaSerLeuSerProValIle-LeuGlyValGln;
37 (3) SerProValIleLeuGlyValGlnGlyGlySerGlnCys;
38 (4) ProIleLeuLysLeuGluProValAsnIleMetGluLeu;